24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825

Diabetes
Resources
Basic InformationLatest News
Diabetes Treatment Failure May Actually Be NonadherenceArtificial Intelligence Can Detect Diabetic RetinopathyMore Than 1 in 10 Patients May Be Overtreated for DiabetesPioglitazone Has Limited Effect in Lipoatrophic DiabetesFracture Risk Higher for Seniors With DiabetesCGM Use in Pregnancy Improves Neonatal OutcomesClosed-Loop Control Benefits T1DM in Prolonged Winter SportHeath Tip: Dining Out If You Have DiabetesExenatide Doesn't Up Cardiovascular Risk in T2DMIncreasing Salt Intake Tied to Diabetes RiskSotagliflozin Linked to Improved Glycemic Control in T1DMGreater Awareness Needed for Potential of T2DM RemissionCan Coffee or Tea Extend Survival With Diabetes?Could Artificial Sweeteners Raise Your Diabetes Risk?Could Swine Flu Be Linked to Type 1 Diabetes?'Upside' to Diabetes Really Isn'tLifestyle Tips for Better Diabetes ControlDiabetes Threatens Kidneys, Vision of Millions of Americans2017 Standards of Medical Care in Diabetes ReleasedBiomarkers Can Predict Rapid Drop in Renal Function in T2DMMany Teens With Type 1 Diabetes Report Disordered EatingCognitive Test Predicts Elderly Insulin Injection SuccessHigher Event Rate of T2DM in Polycystic Ovary SyndromeNovel Genetic Variant in IGF2 Linked to Reduced T2DM RiskFatty Acid Remodeling Seen in T2DM Remission Post Bariatric SxDiacerein Reduces Mean Hemoglobin A1c Levels in T2DMHealth Tip: Risk Factors for PrediabetesTablet Use Encourages Patients to Explore Diabetes RiskOnce-Yearly Counseling Tied to More Physical Activity in T2DMIn T2D, Glycemic Control Up With Continuous Glucose MonitoringSecure Messaging Linked to Better Diabetes ManagementStudies Often Fail to Include Info on T2DM Medication AdherenceIntensive Blood Pressure Tx Aids Those With PrediabetesLifestyle Intervention Only Offers Modest Benefit in Type 2 DiabetesSleep Duration Inversely Linked to Risk Markers of T2DM in KidsCould Big Lifestyle Changes Be Key to Managing Type 2 Diabetes?Variation in Participation in Diabetes Self-Management ClassTeam-Based Online Game May Improve Glycemic Control in T2DArtificial Sweeteners Trick the Brain: StudyCharacteristics of Diabetes in Infancy ExploredImmunotherapy Shown Safe in Type 1 Diabetes Clinical TrialOnline Game Helps Those With Diabetes Control Blood SugarHeart Health Ignored by Many With Type 2 DiabetesMortality Down Only for Gastric Bypass Patients With DiabetesInstagram Shows How Diabetics Really Wear a Glucose MonitorWhat Diabetics Need to Know About Over-the-Counter MedsEngineered Skin Cells Control Type 2 Diabetes in Mice: StudySimilar Defects ID'd for T2DM, Chronic Pancreatitis and DiabetesDiabetes Symptoms Appear to Spread Via Prion-Like MechanismPoor Adherence to Self-Monitoring of Glucose in GDM
Links
Related Topics

Medical Disorders

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy


HealthDay News
Updated: Apr 27th 2017

new article illustration

THURSDAY, April 27, 2017 (HealthDay News) -- Three anti-vascular endothelial growth factor (anti-VEGF) treatments are associated with low rates of diabetic retinopathy (DR) worsening, according to a study published online April 27 in JAMA Ophthalmology.

Susan B. Bressler, M.D., from Johns Hopkins University, and colleagues conducted preplanned secondary analysis of data from a comparative effectiveness trial for center-involved DME in 650 participants during two years of treatment with aflibercept (2 mg), bevacizumab (1.25 mg), or ranibizumab (0.3 mg).

The researchers found that at one year, among 423 nonproliferative DR (NPDR) eyes, 44 of 141 (31.2 percent) treated with aflibercept, 29 of 131 (22.1 percent) with bevacizumab, and 57of 151 (37.7 percent) with ranibizumab had improvement of DR severity (P = 0.004 for aflibercept versus bevacizumab, P = 0.01 for ranibizumab versus bevacizumab, and P = 0.51 for aflibercept versus ranibizumab). At two years, no treatment group differences were identified. Among the 93 eyes with proliferative DR (PDR) at baseline, one-year improvement rates were 75.9 percent for aflibercept, 31.4 percent for bevacizumab, and 55.2 percent for ranibizumab (P < 0.001 for aflibercept versus bevacizumab, P = 0.09 for ranibizumab versus bevacizumab, and P = 0.02 for aflibercept versus ranibizumab). These rates and group differences were maintained at two years.

"All three anti-VEGF treatments were associated with low rates of DR worsening. These data provide additional outcomes that might be considered when choosing an anti-VEGF agent to treat DME," conclude the authors.

Several authors report financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)